> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Baxter Stock Plunges 7%, Wiping Out $962 Million, Despite Raised 2026 Outlook
- URL: https://www.bullished.co/baxter-stock-plunges-7-wiping-out-962-million-despite-raised-2026-outlook-d8db6cce/
- Published: 2026-10-29T17:31:44.000Z
- Updated: 2026-10-29T17:31:44.000Z
- Description: Adjusted profit per share fell on a higher tax rate, and Baxter said it will stop making cephalosporin drugs at its Round Lake plant.
- Author: Matteo Parrino
- Tags: Markets, BAX, Industry: Healthcare

[Baxter International](https://www.bullished.co/tag/bax/) shares fell 7.31% to $23.60 in Thursday trading, as of 1:30 p.m. ET, erasing $962 million in market value, the day after the company [lifted its 2026 outlook](https://www.sec.gov/Archives/edgar/data/0000010456/000001045626000004/bax-20261028.htm?ref=bullished.co) while reporting that third-quarter adjusted earnings per share fell from a year earlier on a higher tax rate.

## Revenue up, adjusted profit down

Baxter reported third-quarter adjusted earnings of [58 cents a share](https://seekingalpha.com/news/4660088-baxter-non-gaap-eps-of-0%5F58-beats-by-0%5F06-revenue-of-2%5F98b-beats-by-70m?ref=bullished.co), down from 69 cents a year earlier. Revenue rose to [$2.98 billion](https://finance.yahoo.com/healthcare/articles/baxter-international-bax-q3-earnings-113504246.html?.tsrc=rss&ref=bullished.co) from $2.84 billion.

The company now expects [full-year adjusted earnings](https://seekingalpha.com/news/4660088-baxter-non-gaap-eps-of-0%5F58-beats-by-0%5F06-revenue-of-2%5F98b-beats-by-70m?ref=bullished.co) of $2.05 to $2.15 a share, up from a prior range of $1.95 to $2.15\. Third-quarter free cash flow was $448 million, the company said, as it completed a tender offer to reduce debt.

On the earnings call, management said Baxter will stop making cephalosporin drugs at its Round Lake plant, giving up $30 million of 2026 operating income. The call linked the exit to an FDA warning letter.

## Giving back a 33% run

Baxter makes healthcare products, including IV solutions, infusion systems, generic injectable drugs and respiratory devices, for hospitals, nursing homes, dialysis centers and patients at home. It reports three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.

The stock was up about 33% year to date as of Wednesday's close, against about 13% for the S&P 500\. Thursday's drop put it on pace for its biggest one-day fall since February 12, when it dropped 16.0%.

CEO Andrew Hider said on the call that a competitor's supply trouble was "not a small piece" of double-digit growth in the Advanced Surgery unit, and warned of tougher comparisons ahead.

Hider's warning of tougher comparisons in Advanced Surgery came on the same call that raised the full-year range.

### Sources

- [Baxter Non-GAAP EPS of $0.58 beats by $0.06, revenue of $2.98B beats by $70M (NYSE:BAX) | Seeking Alpha](https://seekingalpha.com/news/4660088-baxter-non-gaap-eps-of-0%5F58-beats-by-0%5F06-revenue-of-2%5F98b-beats-by-70m?ref=bullished.co) — seekingalpha.com
- [Baxter Q3 Earnings Beat on Broad-Based Growth, '26 Outlook Raised](https://finance.yahoo.com/healthcare/articles/baxter-q3-earnings-beat-broad-144800039.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Baxter International (BAX) Q3 Earnings and Revenues Surpass Estimates](https://finance.yahoo.com/healthcare/articles/baxter-international-bax-q3-earnings-113504246.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Baxter: Q3 Earnings Snapshot](https://finance.yahoo.com/healthcare/articles/baxter-q3-earnings-snapshot-112618961.html?ref=bullished.co) — Associated Press
- [Baxter Intl Q3 2026 Earnings Call Transcript](https://www.benzinga.com/news/26/10/62697378/baxter-intl-q3-2026-earnings-call-transcript?ref=bullished.co) — benzinga.com
- [The company's filing (Baxter International)](https://www.sec.gov/Archives/edgar/data/0000010456/000001045626000004/bax-20261028.htm?ref=bullished.co) — SEC filing
- [Baxter International — Form 10-Q for the quarter ended 2026-06-30 (quarterly results)](https://www.sec.gov/Archives/edgar/data/10456/000162828026051118/bax-20260630.htm?ref=bullished.co) — SEC EDGAR

### More on Baxter International

- [Baxter CEO Says A Rival's Supply Problem Is 'Not A Small Piece' Of 12% Advanced Surgery Growth](https://www.bullished.co/baxter-ceo-says-a-rivals-supply-problem-is-not-a-small-piece-of-12-advanced-surgery-growth-5e0c96e3/)
- [Baxter Ends Cephalosporin Production At Round Lake Plant, Giving Up $30 Million Of 2026 Operating Income](https://www.bullished.co/baxter-ends-cephalosporin-production-at-round-lake-plant-giving-up-30-million-of-2026-dc7109a7/)
- [Baxter Raises 2026 Sales And Profit Outlook, Though Adjusted EPS Falls 16% To $0.58](https://www.bullished.co/baxter-raises-2026-sales-and-profit-outlook-though-adjusted-eps-falls-16-to-0-58-196f7873/)

[All Baxter International (BAX) coverage →](https://www.bullished.co/tag/bax/)